- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Alliance and Schering ink contrast pact
Alliance Pharmaceutical of San Diego and Schering of Berlin, Germany, last month signed an agreement in which Alliance will grant Schering licensing rights to its Imagent US ultrasound contrast agent. Imagent US is based on microbubbles that contain a
Alliance Pharmaceutical of San Diego and Schering of Berlin, Germany, last month signed an agreement in which Alliance will grant Schering licensing rights to its Imagent US ultrasound contrast agent. Imagent US is based on microbubbles that contain a mixture of perfluorochemical vapor and a physiological gas to enhance ultrasound images. It is being targeted for the assessment of cardiac function and perfusion, as well as for the detection of tumors in solid organs. The agent has completed phase II clinical studies for cardiac function.
In exchange for rights to the agent, Schering has agreed to pay licensing fees, reimburse for Alliance's R&D expenses, and purchase a minority interest in Alliance. Imagent US will complement other ultrasound agents in Schering's R&D portfolio, including Levovist and Echovist, which are on the market in some European countries but are not sold in the U.S. So far, Alliance and Imagent US have managed to avoid the recent controversy over ultrasound patents and litigation (SCAN 8/6/97).
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
